Full text is available at the source.
Rational design and combinatorial chemistry of ionizable lipids for RNA delivery
Designing and testing ionizable fats to improve RNA delivery
AI simplified
Abstract
In 2018, LNPs enabled the first FDA approval of a siRNA drug (Onpattro).
- LNPs have facilitated the development of successful RNA-based therapies, including two SARS-CoV-2 vaccines.
- Each FDA-approved LNP formulation employs a unique ionizable lipid, suggesting its importance in mRNA delivery efficiency.
- The review discusses advances in the chemical structures and synthetic methods of ionizable lipids used for RNA delivery.
- Structure-activity relationships of ionizable lipids are explored, indicating their role in enhancing delivery performance.
AI simplified